Patents by Inventor Amanda Ward

Amanda Ward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for modulation nucleic acids through nonsense mediated decay
    Patent number: 10590412
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the amount or activity of a target nucleic acid. In certain embodiments, the amount or activity of a target nucleic acid is modulated through nonsense mediated decay.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: March 17, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Amanda Ward, Frank Rigo
  • MODULATION OF UBE3A-ATS EXPRESSION
    Publication number: 20170362592
    Abstract: Certain embodiments are directed to methods and compounds for inhibiting UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A). Such methods and compounds are useful for. Several embodiments provided herein relate to the discovery that antisense compounds targeting UBE3A-ATS induce paternal expression of UBE3A. Several embodiments are drawn to methods and compounds for inducing paternal expression of UBE3A using antisense compounds targeting UBE3A-ATS within a region of UBE3A-ATS that includes the sequence of the small nucleolar RNA (snoRNA), HBII-85 (also referred to as SNORD116).
    Type: Application
    Filed: November 25, 2015
    Publication date: December 21, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Amanda Ward, Frank Rigo
  • Modulation of UBE3A-ATS expression
    Patent number: 9617539
    Abstract: Certain embodiments are directed to methods and compounds for inhibiting UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A). Such methods and compounds are useful for inducing expression of paternal UBE3A in cells and animals.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: April 11, 2017
    Assignees: Ionis Pharmaceuticals, Inc., Baylor College of Medicine
    Inventors: Frank Rigo, Amanda Ward, Linyan Meng, Arthur L. Beaudet
  • COMPOSITIONS AND METHODS FOR MODULATION NUCLEIC ACIDS THROUGH NONSENSE MEDIATED DECAY
    Publication number: 20160076027
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the amount or activity of a target nucleic acid. In certain embodiments, the amount or activity of a target nucleic acid is modulated through nonsense mediated decay.
    Type: Application
    Filed: April 21, 2014
    Publication date: March 17, 2016
    Applicant: Isis Pharmaceuticals, Inc
    Inventors: Amanda WARD, Frank RIGO
  • MODULATION OF UBE3A-ATS EXPRESSION
    Publication number: 20150191723
    Abstract: Certain embodiments are directed to methods and compounds for inhibiting UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A). Such methods and compounds are useful for inducing expression of paternal UBE3A in cells and animals.
    Type: Application
    Filed: June 25, 2013
    Publication date: July 9, 2015
    Applicants: Baylor College of Medicine, Isis Pharmaceuticals, Inc.
    Inventors: Frank Rigo, Amanda Ward, Linyan Meng, Arthur L. Beaudet
  • Cube charge cover
    Patent number: D735662
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: August 4, 2015
    Assignee: Just Off Center Innovations, LLC
    Inventors: Matthew Ward, Amanda Ward, Guy DeWardener, Cheryl DeWardener